Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18433449 | 0.82 | CNR2 (0.43) | LMNAHPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL12544164 | 0.80 | LMNA (0.39) | LMNAHPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL12567070 | 0.79 | LMNA (0.38) | LMNAHPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL18433607 | 0.79 | LMNA (0.38) | LMNAHPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL2375033 | 0.78 | PIK3CD (0.30) | — | |
| SCHEMBL1499962 | 0.78 | — | — | |
| SCHEMBL20641054 | 0.78 | KMT2A (0.38) | LMNAHPGDKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL28364585 | 0.77 | HPGD (0.49) | LMNAHPGDKMT2ASMN1; SMN2POLB | |
| SCHEMBL12903289 | 0.77 | — | — | |
| SCHEMBL1346216 | 0.76 | CHRM2 (0.43) | LMNAHPGDSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010588-B1 | Organosilicon polyurea polymers, elastomers manufactured therefrom and their use | HENKEL AG & CO KGAA (DE) | 2012-01-04 | — | — | EP | claimed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-01 | — | — | US | disclosed |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-6465495-B1 | INHIBITING DISEASE STATES ASSOCIATED WITH PROTEIN PROTEIN INTERACTION MEDIATED BY A SH2 OR SH3 DOMAIN OR A TYROSINE PHOSPHATASE SUCH AS ALLERGIES, ASTHMA, ANEMIA, AUTOIMMUNE DISEASES, CANCER, INFLAMMATORY DISEASES, OSTEOPOROSIS | OSI PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-0496237-B1 | N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohept[b]indole | PHARMACIA SPA (IT) | 1996-02-14 | — | — | EP | disclosed |
| EP-0496237-A2 | N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohept[b]indole | PHARMACIA S.p.A. (IT) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | LMNA 2394/4885HPGD 3438/4885KMT2A 3701/4885 |
| US-20030195157-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | LMNA 2529/4885HPGD 3503/4885KMT2A 3747/4885 |
| US-20040127423-A1 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | GLP1R, IAPP, GIPR | LMNA 2529/4885HPGD 3503/4885KMT2A 3747/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | LMNA 2394/4885HPGD 3438/4885KMT2A 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.